Cardiovascular measurements
ischemia, Aortic stiffness, arrhythmias
ISCHEMIA, AORTIC STIFFNESS, ARRHYTHMIAS
N-terminal pro-hormone BNP (NT-proBNP) and Troponin T were measured, in addition to electrocardiography. Cardiac strain was non-invasively monitored at baseline, 1 month, 2 months and 3 months following initial administration through NT-proBNP. The Roche cobas e411 analyzer was used alongside the Elecsys proBNP II immunoassay (Roche Diagnostics, Risch-Rotkreuz, Switzerland). Troponin T, a widely accepted marker of ischemia and myocyte damage, was measured at baseline, prior to first infusion and 30 min following first infusion, 1–2 days following first infusion, 2 weeks following first infusion, 1 month (before and after second administration), 1–2 days following second infusion, 2 months and 3 months following initial infusion. The Elecsys Troponin T assay was used (Roche Diagnostics, Risch-Rotkreuz, Switzerland. Electrocardiography was performed at baseline, 1–2 days following first infusion, 1 month, 2 months and 3 months after initial administration to identify any arrhythmias, with measurements of PR, QRS and QTc intervals. Aortic stiffness assessed using measurement of pulse wave velocity carotid-femoral (PWVcf) and Augmentation Index using the Enverdis